Scientists at Hansoh Bio LLC, Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising HER3 (erbB3)-targeting antibodies linked to a cytotoxic drug through a linker.
Since utrophin compensates for lack of dystrophin in mdx mice, which results in a milder phenotype of muscular dystrophy compared to humans, the mdx/utrn-/- mouse has been developed to mimic early onset of muscle dystrophy, severe muscle weakness and premature death.
Researchers from the University of Colorado presented preclinical data for the myeloid leukemia cell differentiation protein Mcl-1 inhibitor S-64315, currently in phase I clinical development for the treatment of hematologic cancers.
Inhibition of OX40 is known to induce and maintain responses in moderate to severe atopic dermatitis (AD). Astria Therapeutics Inc. and Ichnos Sciences Inc. are developing STAR-0310, a YTE-modified (M252Y/S254T/T256E) monoclonal antibody targeting OX40.
The cannabinoid CB1 receptor inverse agonist INV-202 (monlunabant) is in clinical studies at Inversago Pharma Inc. as a potentially first-in-class drug for metabolic disorders, including diabetic kidney disease and obesity.
Cartography Biosciences Inc. announced it has entered into a multiyear, strategic collaboration agreement with Gilead Sciences Inc. to discover and develop therapies for patients with triple-negative breast cancer and adenocarcinoma.
Be Biopharma Inc. has announced the FDA’s clearance of its IND for BE-101, an autologous potentially first-in-class B-cell medicine in development for the treatment of hemophilia B.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of renal failure characterized by development of multiple fluid-filled cysts linked to increased cAMP levels and fibrosis in the kidneys leading to progressive renal failure and need for dialysis or renal transplant.
Bispecific T-cell-engaging antibodies have emerged as therapeutic options for the treatment of cancer, but limitations such as short half-life remain to be addressed. Researchers from Biontech SE reported the preclinical pharmacology and efficacy of BNT-142, a bispecific antibody targeting claudin-6 (CLDN6) and the T-cell marker CD3.
RSS
